{
    "clinical_study": {
        "@rank": "43507", 
        "arm_group": {
            "arm_group_label": "Esophageal barium xray", 
            "description": "We will recruit 20 patients with GERD without dysphagia for an esophageal barium xray for esophageal diameter measurements.\nThe 20 Gastroesophageal Reflux Disease (GERD) patients will complete the Mayo Dysphagia Questionnaire 30-day and the Eosinophilic Esophagitis Actitivy Index (EEsAI) questionnaires"
        }, 
        "brief_summary": {
            "textblock": "The investigators would like to determine if there are patients with PPI responsive\n      Eosinophilic Esophagitis Infiltration that have significant loss of esophageal\n      distensibility suggestive of esophageal fibrosis typical of classic Eosniophilic\n      Esophagitis.\n\n      If this group of patients exists, the investigators would like to determine if they have the\n      typical endoscopic features of EoE rather than those of GERD."
        }, 
        "brief_title": "Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)?", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Erosive Esophagitis", 
        "condition_browse": {
            "mesh_term": [
                "Esophagitis", 
                "Gastroesophageal Reflux", 
                "Eosinophilic Esophagitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Age 18 or older\n\n          -  Have either mild-to-moderate Los Angeles (LA) Classification System grade B,\n             moderately severe LA grade C, or severe LA grade D erosive reflux esophagitis\n\n          -  Or patients having a clinically indicated pH/impedance monitoring on proton pump\n             inhibitor therapy for indications of gastroesophageal reflux disease.\n\n        Exclusion criteria:\n\n          -  Neoplasm of the esophagus or stomach\n\n          -  Inability to read due to: Blindness, cognitive dysfunction, or English    language\n             illiteracy\n\n          -  Disorders which predispose to unreliable responses such as Schizophrenia,\n             Alzheimer's disease or significant memory loss"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with GERD that have been currently diagnosed with erosive esophagitis at\n        endoscopy, at Mayo Clinic Rochester, Minnesota"
            }
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01865825", 
            "org_study_id": "12-009305"
        }, 
        "intervention": {
            "arm_group_label": "Esophageal barium xray", 
            "description": "\u2022Fast for 4 hours prior to the Esophagram (upper GI x-ray). You will drink a liquid that has barium or another contrast agent in it. The radiologist will use the X-ray machine to look at your upper GI tract while you drink the contrast liquid. The x-ray exam should take between 10-15 minutes.\nWe will have patients complete the Mayo Dysphasia Questionnaire-30 day.", 
            "intervention_name": "Esophageal Barium Xray", 
            "intervention_type": "Radiation", 
            "other_name": [
                "GERD", 
                "Erosive Esophagitis", 
                "Esophageal Barium Xray"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Proton Pump Inhibitors"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Erosive Esophagitis", 
            "Gastroesophageal reflux disease"
        ], 
        "lastchanged_date": "October 17, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "PPI Responsive Esophageal Eosinophilia: GERD or Eosinophilic Esophagitis?", 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Jeffrey Alexander, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "We will evaluate endoscopic features of Gastroesophageal Reflux Disease(GERD) by reviewing endoscopic reports and images. The presence of esophageal narrowing, furrows, rings, fragility, and white spots will be noted form the endoscopic reports prior to the initiation of the Provation report system. We will review the endoscopic reports and the endoscopic photographs on those patients evaluated after the Provation report system was initiated. All images will be reviewed by one investigator unaware of the subjects clinical data and name", 
            "measure": "Abnormal esophageal distensibility in patients with PPI responsive Eosinophilic Infiltrates to patients with Eosionophilic esophagitis and Gastroesophageal Reflux Disease.", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01865825"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Jeffrey A Alexander", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "After reviewing endoscopic features of GERD by reviewing endoscopic reports and images. The presence of esophageal narrowing, furrows, rings, fragility, and white spots will be noted form the endoscopic reports prior to the initiation of the Provation report system.  We will determine the relationship of abnormal esophagus distensibility to the endoscopic findings", 
            "measure": "The relationship of abnormal esophageal distensibility to other endoscopic findings of EoE (furrows, rings, fragility, stricture)", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2013"
    }
}